SCHEMBL3365627

SCHEMBL3365627

COC(=O)[C@H]1CC(=O)N(c2ccc(O)cc2)C1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.70
CA1 P00915 2/20 0.70
CA2 P00918 2/20 0.70
CA4 P22748 2/20 0.70
CA6 P23280 2/20 0.70
CA7 P43166 2/20 0.70
CA9 Q16790 2/20 0.70
CA13 Q8N1Q1 2/20 0.70
CA12 O43570 1/20 0.70
CA14 Q9ULX7 1/20 0.70
CA5B Q9Y2D0 1/20 0.70
GAA P10253 1/20 0.70
HPGD P15428 2/20 0.55
TSHR P16473 3/20 0.55
MAPK1 P28482 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.54
BRD4 O60885 1/20 0.54
ATM Q13315 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KMT2A Q03164 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3365457 1.00 ALDH1A1 (0.70) ALDH1A1CA1CA2CA4CA6
SCHEMBL1777398 1.00 ALDH1A1 (0.70) ALDH1A1CA1CA2CA4CA6
SCHEMBL9031939 0.88 MAPK1 (0.70) ALDH1A1CA1CA2CA4CA6
SCHEMBL19793283 0.88 MAPK1 (0.70) ALDH1A1CA1CA2CA4CA6
SCHEMBL6271004 0.87 ALDH1A1 (0.76) ALDH1A1CA1CA2CA4CA6
SCHEMBL1209042 0.87 CA1 (0.68) ALDH1A1CA1CA2CA4CA6
SCHEMBL6265330 0.87 ALDH1A1 (0.70) ALDH1A1CA1CA2CA4CA6
SCHEMBL2215736 0.87 ALDH1A1 (0.68) ALDH1A1CA1CA2CA4CA6
SCHEMBL892079 0.87 ALDH1A1 (0.67) ALDH1A1CA1CA2CA4CA6
SCHEMBL3365950 0.86 ALDH1A1 (0.74) ALDH1A1CA1CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542970-B1 PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
EP-1542969-B1 PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS HOFFMANN LA ROCHE (CH) 2010-03-03 EP disclosed
US-20070032542-A1 Process for the preparation of enantiopure pyrrolidin-2-one derivatives IDING HANS 2007-02-08 US disclosed
US-7151111-B2 4-pyrrolidino-phenyl-benzyl ether derivatives HOFFMANN-LA ROCHE INC. (US) 2006-12-19 US disclosed
US-7148362-B2 Process for the preparation of enantiopure pyrrolidin-2-one derivatives HOFFMANN-LA ROCHE INC. (US) 2006-12-12 US disclosed
US-7122562-B2 4-pyrrolidino-phenyl-benzyl ether derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-17 US disclosed
US-20060122235-A1 Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide IDING HANS 2006-06-08 US disclosed
EP-1664323-A1 ENZYMATIC SYNTHESIS OF ENATIOPURE INTERMEDIATES BY MEANS OF CHOLESTEROLESTERASE FROM YEASTS F. HOFFMANN-LA ROCHE AG (CH) 2006-06-07 EP disclosed
US-7037935-B2 4-Pyrrolidino-phenyl-benzyl ether derivatives HOFFMANN-LA ROCHE INC. (US) 2006-05-02 US disclosed
EP-1542970-A1 PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-22 EP disclosed
US-20050065204-A1 Process for the preparation of enantiopure pyrrolidin-2-one derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-03-24 US disclosed
WO-2005026373-A1 ENZYMATIC SYNTHESIS OF ENATIOPURE INTERMEDIATES BY MEANS OF CHOLESTEROLESTERASE FROM YEASTS F. HOFFMANN-LA ROCHE AG (CH) 2005-03-24 WO disclosed
US-20040116707-A1 4-Pyrrolidino-phenyl-benzyl ether derivatives HOFFMANN-LA ROCHE INC. 2004-06-17 US disclosed
US-20040106650-A1 4-Pyrrolidino-phenyl-benzyl ether derivatives HOFFMANN-LA ROCHE INC. 2004-06-03 US disclosed
WO-2004026825-A1 PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106650-A1 4-Pyrrolidino-phenyl-benzyl ether derivatives MAOB, MAOA, COMT ALDH1A1 556/4885CA1 3797/4885CA2 4715/4885
US-20060122235-A1 Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide MAOA, MAOB, PNPO ALDH1A1 385/4885CA1 3194/4885CA2 4120/4885
US-20050065204-A1 Process for the preparation of enantiopure pyrrolidin-2-one derivatives MAOB, MAOA, CYP1B1 ALDH1A1 249/4885CA1 4459/4885CA2 4203/4885
US-20070032542-A1 Process for the preparation of enantiopure pyrrolidin-2-one derivatives MAOB, MAOA, CYP1B1 ALDH1A1 249/4885CA1 4459/4885CA2 4203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.